<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02702674</url>
  </required_header>
  <id_info>
    <org_study_id>propranolol</org_study_id>
    <nct_id>NCT02702674</nct_id>
  </id_info>
  <brief_title>The Effect of Coadministration of Oral Propranolol to Oxytocin on Induction of Labor</brief_title>
  <official_title>The Effect of Coadministration of Oral Propranolol to Oxytocin on Induction of Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of coadministration of oral propranolol to oxytocin on induction of labor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study hypothesis:&#xD;
&#xD;
      Oral propranolol when used with oxytocin during the process of labor may reduce labor&#xD;
      interval and decrease the rate of cesarean delivery.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      The patients will be recruited from the women attending obstetrics reception room, in Ain&#xD;
      Shams University Maternity Hospital.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      After taking informed consent, all patients recruited in the study will undergo complete&#xD;
      clinical examination and detailed medical history will be obtained along with necessary&#xD;
      laboratory investigations and ultrasound. Each patient will have a case record form in which&#xD;
      the following data will be recorded:&#xD;
&#xD;
        1. History: personal (age, duration of marriage), present illness (any current medical or&#xD;
           surgical diseases and any current medication), obstetric history (including parity,&#xD;
           gestational age, obstetric complications) and past medical history(especially cardiac&#xD;
           problems).&#xD;
&#xD;
        2. Clinical examination:&#xD;
&#xD;
             1. General examination: assessment of vital data, cardiac and chest auscultation to&#xD;
                exclude contraindications for drug administration.&#xD;
&#xD;
             2. Abdominal examination: assessment of fundal level and contractions if present.&#xD;
&#xD;
             3. Pelvic examination: assessment of Bishop score, membrane status and fetal&#xD;
                presentation.&#xD;
&#xD;
        3. Investigations:&#xD;
&#xD;
             1. Routine investigations will be done e.g., Full blood count, CRP titre.&#xD;
&#xD;
             2. Pelvi-abdominal U/S (confirm fetal life, placental location, fetus parameters,&#xD;
                amniotic fluid index, expected fetal weight).&#xD;
&#xD;
      Steps:&#xD;
&#xD;
        1. Informed consent will be obtained from parents or guardians of patients who are invited&#xD;
           to participate in the research after explanation of benefits and risks of this trial.&#xD;
&#xD;
        2. A capsule containing 20 mg propranolol to the first group (propranolol plus oxytocin)&#xD;
           and a similar capsule as a placebo to the second group (oxytocin plus placebo) are&#xD;
           administrated orally before beginning induction. Oral capsules are repeated after 8 h,&#xD;
           if three forceful contractions are not obtained during 10 min.&#xD;
&#xD;
        3. Induction will be initiated with a dose of 2 mIu/min and increased by 2 mIu/min every 15&#xD;
           min until three forceful contractions be obtained for 10 min, or to a maximum dose of 30&#xD;
           mIu/min. Then, continue at this rate for 8 h. If patients entered the active phase of&#xD;
           labor (cervical dilatation = 3-4 cm), induction continue until delivery.&#xD;
&#xD;
        4. Amniotomy is performed when cervical dilation reached 5 cm, if the membrane has not been&#xD;
           ruptured spontaneously.&#xD;
&#xD;
        5. The partogram will be used to monitor the fetal heart rate, membrane status, cervical&#xD;
           dilation and effacement, station of the fetus, uterine contractions, maternal pulse,&#xD;
           maternal blood pressure, maternal temperature.&#xD;
&#xD;
        6. If there is no response to induction on the second day, a cesarean section will be&#xD;
           performed.&#xD;
&#xD;
        7. The participants are followed up until delivery.&#xD;
&#xD;
      Safety Considerations:&#xD;
&#xD;
      If the parturient has hyperstimulation of contractions (in a situation with more than 5&#xD;
      contractions/10 min, duration of contraction &gt; 90 sec, interval of contraction less than 2&#xD;
      min, or fetal distress), the induction will be stopped, and the parturient is kept in left&#xD;
      lateral position and given oxygen, and intravenous dextrose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>duration of first stage of labour</measure>
    <time_frame>24 hours</time_frame>
    <description>duration of first stage of labour in hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of cesarean section</measure>
    <time_frame>48 hours</time_frame>
    <description>number of participants eventually undergo cesarean section</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>24 hours</time_frame>
    <description>Apgar score at minute 1 and minute 5 following delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Poor; Labor</condition>
  <arm_group>
    <arm_group_label>propranolol plus oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>121 patients who will receive a capsule containing 20 mg propranolol (propranolol plus oxytocin) administrated orally before beginning induction and repeated after 8 hours if no sufficient uterine contractions reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo plus oxytocin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>121 control patients who will receive a similar capsule as a placebo (oxytocin plus placebo) before beginning induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>propranolol 20 mg given before induction of labor</description>
    <arm_group_label>propranolol plus oxytocin</arm_group_label>
    <other_name>indral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>starch tablet containing no active drug material given before induction of labor</description>
    <arm_group_label>placebo plus oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>intravenous infusion of oxytocin</description>
    <arm_group_label>placebo plus oxytocin</arm_group_label>
    <arm_group_label>propranolol plus oxytocin</arm_group_label>
    <other_name>syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gestational age above 37 weeks.&#xD;
&#xD;
          2. Fetal life positive on ultrasound.&#xD;
&#xD;
          3. Bishop score &gt; 5.&#xD;
&#xD;
          4. Primiparous women.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. history of uterine surgery&#xD;
&#xD;
          2. polyhydramnios&#xD;
&#xD;
          3. contraindications to Î²-adrenergic agents, such as systolic blood pressure less than&#xD;
             100 mmHg or pulse rate less than 60/min and more than 120/min&#xD;
&#xD;
          4. history of any known cardiac disease&#xD;
&#xD;
          5. mother's pulmonary or metabolic disorders&#xD;
&#xD;
          6. fetal distress&#xD;
&#xD;
          7. estimated weight of the fetus more than 4 kg by ultrasound of cephalic presentation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amr A Riad, MD</last_name>
    <phone>01005347179</phone>
    <phone_ext>+2</phone_ext>
    <email>amr.riad@med.asu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams maternity hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>February 13, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>March 3, 2016</last_update_submitted>
  <last_update_submitted_qc>March 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Amr Ahmed Mahmoud Riad</investigator_full_name>
    <investigator_title>Lecturer of obstetrics and gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

